D'Orazio & Associates’s Biogen BIIB Stock Holding History

D'Orazio & Associates’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$320K	Sell	1,481 -296	-17%	-$56.6K	0.04%	210
2026 Q1	$326K	Buy	+1,777	New	+$327K	0.04%	182
2021 Q4	–	Sell	-71	Closed	-$20K	–	169
2021 Q3	$20K	Buy	+71	New	+$23.3K	﹤0.01%	390
2019 Q3	–	Sell	-16	Closed	-$4K	–	350
2019 Q2	$4K	Hold	16	–	–	﹤0.01%	282
2019 Q1	$4K	Buy	+16	New	+$5.04K	﹤0.01%	284

Other funds holding BIIB

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

D'Orazio & Associates's BIIB Position: Q2 2026 in Review

D'Orazio & Associates reduced its Biogen (BIIB) stake by 17% in Q2 2026, selling an estimated $56.6K and leaving 1,481 shares worth $320K. The position accounts for 0.04% of the portfolio, ranked #210.

D'Orazio & Associates first reported a position in BIIB in Q1 2019 and has held it in 5 quarters since. The position peaked at $326K in Q1 2026. 1,038 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

D'Orazio & Associates held 1,481 shares of Biogen worth $320K as of Q2 2026.
D'Orazio & Associates sold 296 Biogen shares in Q2 2026, an estimated $56.6K.
Biogen made up 0.04% of D'Orazio & Associates's portfolio in Q2 2026, its #210 holding.
D'Orazio & Associates first reported a position in Biogen in Q1 2019 and has held it in 5 quarters since.
D'Orazio & Associates's Biogen position peaked at $326K in Q1 2026.
1,038 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on D'Orazio & Associates's 13F filing for Q2 2026, filed 28 Jul 2026.